Complete financial analysis of Omeros Corporation (OMER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omeros Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Aeon Fantasy Co., Ltd. (4343.T) Income Statement Analysis – Financial Results
- Namoi Cotton Limited (NAM.AX) Income Statement Analysis – Financial Results
- Maj Invest – Investeringsforeningsbevis (MAJEMV.CO) Income Statement Analysis – Financial Results
- Ingredion Incorporated (INGR) Income Statement Analysis – Financial Results
- Rural Funds Group (RFNDF) Income Statement Analysis – Financial Results
Omeros Corporation (OMER)
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 73.81M | 111.81M | 29.87M | 64.83M | 41.62M | 13.51M | 539.00K | 1.60M | 6.02M | 4.52M | 2.11M | 1.44M | 1.17M | 1.92M | 200.00K | 0.00 |
| Cost of Revenue | 69.78M | 952.00K | 1.39M | 902.00K | 865.00K | 512.00K | 1.08M | 1.41M | 1.04M | 26.73M | 18.33M | 18.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.78M | -952.00K | -1.39M | 72.91M | 110.94M | 29.36M | 63.75M | 40.21M | 12.47M | -26.19M | -16.73M | 6.00M | 4.52M | 2.11M | 1.44M | 1.17M | 1.92M | 200.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 98.78% | 99.23% | 98.29% | 98.34% | 96.61% | 92.29% | -4,858.81% | -1,045.38% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 114.87M | 112.72M | 118.78M | 110.82M | 109.70M | 89.86M | 55.60M | 50.70M | 48.38M | 47.95M | 36.30M | 31.92M | 23.72M | 23.47M | 16.93M | 17.85M | 15.92M | 20.53M | 5.80M |
| General & Administrative | 0.00 | 50.67M | 54.84M | 72.70M | 64.63M | 51.72M | 52.04M | 43.78M | 35.33M | 22.60M | 15.82M | 10.99M | 8.22M | 8.75M | 0.00 | 7.85M | 10.40M | 3.63M | 0.00 |
| Selling & Marketing | 0.00 | 3.20K | 7.80K | 5.60K | 8.00K | 2.50M | 300.00K | 672.00K | 885.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.66M | 50.67M | 54.84M | 72.70M | 64.63M | 51.72M | 52.04M | 43.78M | 35.33M | 22.60M | 15.82M | 10.99M | 8.22M | 8.75M | 5.27M | 7.85M | 10.40M | 3.63M | 1.90M |
| Other Expenses | -69.78M | 0.00 | 1.74M | 654.00K | 1.55M | 1.78M | 1.44M | 945.00K | 1.03M | -207.00K | 574.00K | 130.00K | 0.00 | 0.00 | 0.00 | 372.00K | -125.00K | 179.00K | 0.00 |
| Operating Expenses | 94.75M | 163.39M | 173.62M | 183.51M | 174.32M | 141.58M | 107.64M | 94.48M | 83.71M | 70.55M | 52.12M | 42.91M | 31.93M | 32.21M | 22.20M | 25.70M | 26.32M | 24.15M | 7.71M |
| Cost & Expenses | 164.53M | 163.39M | 173.62M | 184.41M | 175.19M | 142.09M | 108.72M | 95.89M | 84.75M | 70.55M | 52.12M | 42.91M | 31.93M | 32.21M | 22.20M | 25.70M | 26.32M | 24.15M | 7.71M |
| Interest Income | 0.00 | 4.06M | 17.93K | 654.00K | 22.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 333.00K |
| Interest Expense | 14.50M | 22.70M | 19.67M | 26.75M | 22.66M | 16.25M | 11.03M | 7.82M | 3.57M | 3.47M | 2.37M | 1.73M | 1.88M | 1.54M | 2.20M | 335.00K | 151.00K | 91.00K | 0.00 |
| Depreciation & Amortization | 920.00K | 952.00K | 1.39M | 1.62M | 1.79M | 962.00K | 551.00K | 300.00K | 209.00K | 326.00K | 302.00K | 320.00K | 435.00K | 472.00K | 451.00K | 434.00K | 375.00K | 232.00K | 341.00K |
| EBITDA | -163.61M | -162.44M | -172.23M | -168.02M | -144.25M | -122.47M | -41.90M | -58.63M | -71.31M | -69.88M | -37.13M | -36.40M | -26.23M | -27.24M | -18.44M | -24.09M | -22.57M | -22.45M | -7.37M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -148.95% | -55.30% | -369.76% | -65.48% | -128.15% | -519.71% | -13,026.90% | -3,102.50% | -610.35% | -612.80% | -1,521.33% | -1,535.87% | -2,027.26% | -1,255.69% | -11,771.00% | 0.00% |
| Operating Income | -164.53M | -163.39M | -173.62M | -110.60M | -63.38M | -112.22M | -43.90M | -54.28M | -71.24M | -70.01M | -50.52M | -36.89M | -27.41M | -30.11M | -20.76M | -24.53M | -24.40M | -23.95M | -7.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -149.84% | -56.69% | -375.73% | -67.71% | -130.42% | -527.34% | -12,988.50% | -3,157.25% | -612.50% | -605.88% | -1,430.21% | -1,437.53% | -2,096.15% | -1,268.69% | -11,976.50% | 0.00% |
| Total Other Income/Expenses | -10.39M | -18.64M | -17.93M | -39.47M | -21.10M | -27.46M | -9.59M | -12.47M | -3.86M | -3.67M | 10.72M | -1.56M | -1.14M | 855.00K | -331.00K | 698.00K | 1.31M | 1.18M | 341.00K |
| Income Before Tax | -174.92M | -182.03M | -191.55M | -150.07M | -84.49M | -139.69M | -53.48M | -66.75M | -75.10M | -73.67M | -39.80M | -38.44M | -26.66M | -27.72M | -18.89M | -23.83M | -23.09M | -22.78M | -7.37M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -203.31% | -75.57% | -467.68% | -82.50% | -160.38% | -555.90% | -13,668.46% | -2,487.25% | -638.39% | -589.35% | -1,316.67% | -1,307.96% | -2,036.50% | -1,200.78% | -11,388.50% | 0.00% |
| Income Tax Expense | 0.00 | -210.81M | -365.76M | -12.01M | 22.42M | -12.93M | 11.92M | 8.46M | 4.39M | 2.94M | 2.94M | 1.54M | 1.14M | -855.00K | 331.00K | 707.00K | 26.00K | 270.00K | 0.00 |
| Net Income | -117.81M | 28.78M | 194.24M | -138.06M | -106.91M | -126.76M | -53.48M | -66.75M | -75.10M | -73.67M | -39.80M | -38.44M | -28.55M | -29.25M | -21.09M | -23.83M | -23.09M | -22.78M | -7.37M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -187.04% | -95.62% | -424.39% | -82.50% | -160.38% | -555.90% | -13,668.46% | -2,487.25% | -638.39% | -630.99% | -1,389.60% | -1,460.46% | -2,036.50% | -1,200.78% | -11,388.50% | 0.00% |
| EPS | -1.88 | 0.46 | 3.12 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -8.26 | -1.62 | -1.60 | -0.52 |
| EPS Diluted | -1.88 | 0.46 | 3.12 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -8.26 | -1.62 | -1.60 | -0.52 |
| Weighted Avg Shares Out | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 2.88M | 14.27M | 14.27M | 14.27M |
| Weighted Avg Shares Out (Dil) | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 2.88M | 14.27M | 14.27M | 14.27M |
Omeros: Off To Never-Never Land
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript
Omeros Corporation Reports Second Quarter 2022 Financial Results
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
Why Omeros Corporation Stock Is Marching Higher Today
FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Why Omeros Stock Is Freefalling Today
Omeros: On Death's Door
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports